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Interleukin-5 (IL-5) exerts a wide range of effect on eosinophils. It supports the proliferation and terminal differentiation of eosinophil precursors' as well as the prolonged survival of eosinophils in vitro.' IL-5 is also a selective chemotactic agent for eosinophils and a potent activator of eosinophil functions such as cytotoxicity and mediator release." Previous studies have reported the T-cell dependency of blood eosinophilia and/or the presence of IL-5 mRNA or protein in lymphocytescollected in various eosinophilia-associated disorders."-I3 However, the cellular sources of IL-5 remained to be elucidated. We have recently shown that tissue eosinophils from patients with coeliac disease, as well as highly purified blood eosinophils from patients with eosinophilic disorders, express IL-5 mRNA.14 These results have been recently confirmed by Broide et al," who detected the expression of IL-5 mRNA in postallergen challenge eosinophils obtained by bronchoalveolar lavage in asthmatic patients.
In the present study, we analyze, by electron microscopy, immunohistochemistry, and in situ hybridization, the presence of activated eosinophils, the localization of cationic proteins, and the expression of IL-5 mRNA and protein in endomyocardial biopsies or necropsy samples from four eosinophilic patients with endom yocardial diseases. By in situ hybridization and immunohistochemistry, we tested the hypothesis that in vivo activated eosinophils can synthesize IL-5 in endomyocardial lesions of patients with eosinophilia and heart failure and that this local secretion of IL-5 might participate in autocrine activation of eosinophils. In addition, the efficacy of a-interferon (a-IFN) in this disease was evaluated by clinical and biologic parameters.
MATERIALS AND METHODS

Patients.
The study included four patients with eosinophilic diseases associated with severe cardiac failure. For each patient, blood and tissue markers of disease activity were analyzed after informed consent was obtained. A 47-year-old woman (case no. 1) and 50-year-old man (case no. 2), both fulfilling the diagnostic criteria for idiopathic hypereosinophilic syndrome (HES),I6 developed chronic endomyocardial fibrosis. Conventional treatment with prednisone (30 to 60 mg/d) and hydroxyurea (1 to 2 g/d) was started. Four months after the initiation of therapy, aggravation of heart failure was appreciated by clinical and biologic parameters, including cardiac catheterization, echocardiography, and electrocardiography. a-IFN therapy was then started after informed consent was obtained. A daily dose of 5 million units for 5 days per week, administered subcutaneously, was administered during the time of the study. A 61-year-old woman (case no. 3) presented with dyspnea 4 days before admission. She fulfilled the diagnosis criteria of HES and developed chronic endomyocardial fibrosis. Despite treatment with prednisone (60 mg/d), cardiac decompensation was rapidly progressive and she died from intractable cardiac arrhythmias. A 7-year-old girl (case no. 4) presenting with dyspnea (60/min) and tachycardia ( 150/mn) developed sudden cardiac deterioration related to a postmortem diagnosis of eosinophilic myocarditis. She never related having drug hypersensitivity. While emergency mea- sures were being instituted and prednisone treatment started, the child died with a pattern of infarction on electrocardiography.
Eosinoplrilpirri~carion procedirre. The processing of blood samples for eosinophil purification was the same for the four patients. Blood eosinophils were purified by centrifugation on discontinuous metrizamidegradients, as previously described? Using this cell purification procedure, hypodense eosinophils that sediment in 20% 22%, and 23% metrizamide solutions were separated from eosinophils that sediment in fractions of intermediate density (24% metrizamide solution) or high density zone (25% metrizamide solution).
The degree of eosinophil purity and the yield of eosinophils recovered were evaluated for each fraction (cytocentrifuge smears and giemsa staining) and the percentage of hypodense eosinophils was calculated.
Measrrretnenr qf ECP and sohhli~ IL-2 riwpror (slL-2R). The serum levels of ECP were evaluated in the four patients. Ten milliliters of peripheral blood was collected by venipuncture for each patient at the time ofbiopsy or death and kept at 4°C before centrifugation at 850g for IO minutes. Collected sera were stored at -20°C before analysis. ECP levels were determined by means of a commercially available double-antibody radioimmunoassay (ECP/ RIA; Pharmacia, Uppsala, Sweden). Serum levels of slL-2R were evaluated in the four patients using a sandwich enzyme immunoassay (Cell Free: T Cell Sciences, Inc. Cambridge, MA) as previously described." hforpholo~~ic s~rrdicx Samples of endocardium and myocardium were obtained by cardiac biopsy for patients no. I and 2 and at necropsy in the two other patients (Table I) . Specimens were immediately fixed in fresh 4% paraformaldehyde/phosphate-buffered saline, embedded in paraffin, and further processed for histologic examinations. Alternatively, specimens were fixed in 1% glutaraldehyde/cacodylate. embedded in Epon. and processed for ultrastructural studies.
Indirect immunoenzymatic methods were used to detect the presence of granule cationic proteins and the Charcot Leyden crystal (CLC) with the followingantibodies(Ab): EG2.'*a mouse monoclonal Ab (MoAb) directed against the secreted form of ECP, kindly given by Dr Po Chun Tai In sirir liyhridizurion. The cDNA for human IL-5 was subcloned into the Blue Script vector by standard techniques. Radiolabeled RNA probes were prepared as previously de~cribed.'~ In brief, linearized plasmid was used as the template for the synthesis in vitro of a "S-labeled RNA probe (Amersham-France, Les Ullis, France) complementary to the cellular IL-5 mRNA (antisense probe). RNA was also transcribed in the opposite direction and used as a negative control (sense probe). Antisense or sense probes (4,150 cpm/mm2) were hybridized with cardiac samples as previously de~cribed.'~ To inhibit nonspecific binding of "S, tissues and cells were acetylated in 0. I mol/L triethanolamine for 5 minutes and then in acetic anhydride 0.25% triethanolamine for 10 minutes before hybridization. To further avoid nonspecific binding to eosinophils. prehybridization was performed with a solution containing a nonradiolabeled S-UTP irrelevant probe for at least 2 hours at 42°C. dithiothreitol was added to the hybridization buffer, and RNAse A was used for posthybridization washings." After development of the emulsion, tissue sections or cytospin preparations were then stained with May-Grunwald Giemsa for examination by light microscopy.
Blood hypodense eosinophils were collected by metrizamide centrifugation and the degree of eosinophil purity evaluated by MayGrunwald Giemsa differential counting on cytocentrifuged preparations. In all cases, eosinophil purity was greater than 950/0. These cells were resuspended at a concentration of 0.8 X IO6 cells/mL of Hanks' Balanced Saline Solution and loaded onto gelatin-coated slides(0.8 X I Os cells/slides) bycytocentrifugation. Thecytopreparations were immediately fixed for 20 minutes in 4% paraformaldehyde and stored at -20°C until use. In situ hybridization was then performed using the same technical conditions and the same probes as for tissue sections.
S/a/i.srica/ ana/wi.s. The relationships between ECP levels, slL-2R levels. and blood eosinophilia were determined using the nonparametric Spearman's rank correlation test (P < .05 was considered significant).
RESULTS
Blood m a r k m of clisc.ase aclivity. To investigate the state of activation of blood eosinophils, various biologic parameters were evaluated. First. the separation of eosinophil phenotypes was performed by centrifugation of blood leukocytes on discontinuous metrizamide gradients, as previously de~cribed.~ Using the same separation procedure for the four patients. hypodense eosinophils, sedimenting in fractions of low density (20% to 23% metrizamide. density [d] < I. 135) could be collected and their numbers compared with those of eosinophils with intermediate or high density (>23% metrizamide, d > 1.135). As illustrated in Table 2 , a very high proportion of hypodense eosinophils (92% to 97%) was observed in all four patients compared with that in historical controls.
The presence of one eosinophil granule cationic protein, ECP, in the serum or biologic fluids ofpatients after eosinophil degranulation can be a valuable and objective parameter in monitoring disease activity, particularly after treatment.*' Results shown in Table 2 indicated significantly increased serum levels of ECP in the four patients compared with normal values. Because several studies have suggested a relationship between T-lymphocyte stimulation and eosinophil activation, and because it has been recently shown that patients with HES have increased levels of sIL-~R," serum levels of IL-2R were evaluated. As shown in Table 2 , very high values of slL-2R were detected in the serum ofthe four patients.
The deterioration of heart failure in two patients (cases no. I and 2) despite conventional treatment (prednisone/ hydroxyurea) led to the initiation of a-IFN therapy. Such therapy resulted in a dramatic beneficial response, with a marked improvement in cardiac function. As shown in Fig  I, philia, ECP, and sIL-2R) showed a parallel decrease of blood eosinophilia, ECP levels, and sIL-2R levels during a-IFN therapy. In the case of patient no. 2, a positive correlation could be established during a-IFN therapy between serum ECP levels and eosinophilia ( r = .764; P < .Ol), between ECP levels and sIL-2R values ( r = S37; P < .005), and between serum sIL-2R values and eosinophilia ( r = .698; P < .Ol), indicating a significant association between these three parameters.
Morphologic studies (Table 1) showed that, in the case of endomyocardial biopsies (cases no. 1 and 2), eosinophils were found in edematous interfibrillar areas. There were no other inflammatory cells, no fiber vacuolisation, and no vasculitis. Electron microscopy showed eosinophils surrounded by numerous free granules due to lysis of the cytoplasm (Fig 2) . Some granules showed an inverted density, indicating a state of eosinophil activation. Myocardial fibres were not damaged.
In cases no. 3 and 4, necropsic examination of the heart showed a voluminous adhesive thrombus within the left ventricule (Fig 3) . No valvular damage was observed. No evidence of thrombosis was found upon dissection of the coronary vessels. Histologically, eosinophils were numerous, particularly in the endomyocardial area where the thrombus was organized. Fibrin deposits were found within the lumen of some intramyocardial vessels. Large areas of myocardial necrosis were found in case no. 3; periveinular fibrosis was found in case no. 4. Electron microscopy showed alterations of eosinophil granules and cytoplasm, whereas myocardial fibers were damaged with loss of myofilaments or complete necrosis. CLC were numerous within the thrombus and adjacent endocardium.
In cases no. 1 and 2, immunostaining showed extracellular deposits of the four eosinophil proteins, with a predominance of MBP and CLC in edematous interfibrillar areas. In cases no. 3 and 4, immunostaining showed extracellular deposition of all four eosinophil proteins (ECP, MBP, EDN, and CLC). Very few intact eosinophils were found on histo-
Tissue markers of disease activity.
logic sections (Fig 4A) , whereas ECP deposition was particularly intense in the endomyocardial area of thrombus adhesion (Fig 4B) .
Positive in situ hybridization signals were observed on numerous cells infiltrating myocardial sections of the four patients only with the antisense IL-5 RNA probe and not with the sense probe. Similar label intensity was obtained in the myocardium of the four patients. Examination ofthe tissues at a higher magnification showed that same-labeled cells had a polylobulated nucleus (Fig 5A) . To detect the presence of IL-5 protein in eosinophils from these patients, immunostaining of cardiac tissues was performed using antihuman IL-5 MoAb (Glaxo Research Group) and the APAAP technique described above. Results ofone representative experiment performed on patient no. 4 show an intense staining of cells with a polylobulated nucleus with antihuman IL-5 (Fig 5B) . An overall study performed on the myocardial sections of all four patients showed that approximately 60% to 90% cardiac eosinophils were positively labeled both by in situ hybridization and by immunostaining. Not only tissue cells but also highly purified blood eosinophils from the same patients were submitted to in situ hybridization with the IL-5 probe and human-IL-5 MoAb. As shown in Fig 5C , eosinophils expressed IL-5 mRNA, whereas no positive signal was detected with the control IL-5 sense probe (Fig 5D) , confirming the idea that tissue and blood eosinophils could express the IL-5 mRNA. Antihuman-IL-5 MoAb used on the same cytopreparations of purified blood eosinophils showed an intense staining in the cytoplasm of eosinophils (Fig 5E) when the control with an irrelevant antibody was negative (Fig 5F) . This finding confirmed the idea that tissue and blood eosinophils could produce the IL-5 protein.
Because blood eosinophil counts returned to normal levels after treatment with a-IFN and cardiac biopsy could not be repeated in treated patients, the effect of a-IFN on IL-5 synthesis by blood and tissue eosinophils could not be appreciated in these patients after treatment. The high morbidity and mortality of eosinophilic diseases are often related to heart failure.'-3 Chronic, subacute, or acute forms of cardiomyopathy have been described.233 One of their common features is the presence of elevated numbers of blood eosinophils together with eosinophil infiltration in the cardiac tissue. Previous findings have suggested that eosinophils could present signs of activation in eosinophilic disorders associated with visceral in~olvement.~ Increased blood numbers of hypodense, degranulated, and vacuolated eosinophils have been indeed found in these pat i e n t~.~.~ The cytotoxic potential of hypodense eosinophils and their basic granule proteins has been previously reCardiac damage might be related to the toxic effects of activated eosinophils, because immunohistochemical studies have shown the deposition of eosinophil cationic granule proteins in endomyocardial lesions of patients with HES? in acute necrotizing eosinophilic myocarditi~,~ and in syndromes associated with fibrosis.22 In the present work, markers of eosinophil activation were detected both in the blood and in the cardiac tissue of four patients with eosinophilic heart disease. However, the mechanisms responsible for activation and release of toxic mediators remain to be identified. The participation of activated blood T lymphocytes has been postulated, because very high levels of sIL-2R can be detected in the sera of patients with HES associated with visceral involvement.21 It has been recently shown that the serum sIL-2R level is a sensitive and reliable quantitative marker of mononuclear cell a~t i v a t i o n .~~ In the present study, changes in serum sIL-2R values correlated with the absolute number of blood eosinophils and serum ECP levels throughout evolution of the eosinophilic disease. sIL-2R might arise from eosinophils themselves, as we have previously reported that hypodense eosinophils can express the IL-2R a-chain on the cell surface.24 Moreover, it has been recently shown that IL-5 can also be produced by cell types The majority of eosinophils from endomyocardial tissues of patients with eosinophilic heart disease expressed IL-5 mRNA and synthetized IL-5 protein. In all cases, eosinophils were activated as shown in cardiac biopsies by ultrastructural changes and by immunohistochemical staining with EG2, an MoAb that binds to the activated form of ECP.'* Therefore, the local synthesis of IL-5 in endomyocardial tissues might contribute to the proliferation and activation of eosinophils by enhancing the release of cationic proteins that could be involved in the progression of cardiac lesions. It has to be mentioned that, in a separate study, the levels of IL-5 secreted by purified blood eosinophils upon activation with various stimuli have been measured by an enzyme-linked immunosorbent assay and reached values up to 250 pg/ I X 1 O6 cells, which are capable of inducing the proliferation of an IL-5-dependent B-cell line (Dubucquoi et al submitted for publication). An autocrine mechanism in which stimulated eosinophils both release and respond to IL-5 could therefore be involved, because IL-5 membrane receptors have been described on hypodense blood and tissue eosinophils." Although they indicate that eosinophils might contribute to the local production of IL-5, these results do not imply that eosinophils represent the only source of IL-5, because previous studies have shown the production of IL-5 by T cells from patients with various HES."-13 However, the present study did not allow us to assess the relative significance of IL-5 derived from T cells and eosinophils in the etiology of the disease because 95% of the cells infiltrating the lesions were eosinophils. The low percentage of infiltrating lymphocytes was not sufficient to perform statistically significant analysis. In a more recent study, we could show that both EGZpositive eosinophils and EG2-negative T cells expressed IL-5 mRNA and immunoreactive protein in the skin of patients with atopic dermatitis (Tanaka et al, submitted for publication).
Synthesis of IL-5 by blood and cardiac eosinophils.
In vitro functional studies of the effects of d F N on eosinophils have led to variable results. a-IFN suppresses eoFor personal use only. on October 30, 2017. by guest www.bloodjournal.org From sinophilic colony growthz7 and decreases eosinophil peroxidase and hydrogen peroxide release in response to stimuli." However, it has been shown that a-IFN activates some eosinophil function^.'^ After the establishment of its suppressive effects on granulocyte-macrophage colonies in vitro, a-IFN has been recently administered to patients with HES, resulting in dramatical clinical and hematologic improvement.30,31 More recently, a beneficial clinical response associated with a rapid decrease in sIL-2R levels and blood eosinophilia has been reported in six cases of malignant HES treated with O~-IFN.~' In the present study, two patients were clinically improved after a-IFN therapy, with a significant decrease in blood eosinophil counts, in serum ECP, and in sIL-2R levels, all considered as useful indicators of disease activity in HES patients.2092' Experiments are now in progress to explore the effects of a-IFN on IL-5 synthesis by eosinophils from patients with eosinophilic heart diseases.
The mechanisms determining local eosinophil accumulation and activation in tissues and particularly in cardiac tissues, in which eosinophils induce dramatic pathologic changes, have still to be explored. However, the present results suggest that IL-5 synthesized by eosinophils might play a major role in the chemoattraction of eosinophils and the release oftoxic mediators from eosinophils, providing, therefore, an important autocrine activation pathway.
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